Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.
about
Gender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010)beta-Estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBLHepatic profile analyses of tipranavir in Phase II and III clinical trialsSex differences in drug disposition.Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi.Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individualsHIV or HIV-therapy? Causal attributions of symptoms and their impact on treatment decisions among women and men with HIV.ER-β mediates 17β-estradiol attenuation of HIV-1 Tat-induced apoptotic signaling.How are women living with HIV in France coping with their perceived side effects of antiretroviral therapy? Results from the EVE study.Considerations for the antiretroviral management of women in 2008.Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda.Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.Levamisole-Contaminated Cocaine Use in HIV-Infected and Uninfected Unstably Housed Women.Sex differences in pharmacokinetics and pharmacodynamics.Impact of Gender on Long-Term Treatment Outcomes of Highly Active Antiretroviral Therapy (HAART) in the TREAT Asia HIV Observational Database.Time for gender mainstreaming in editorial policiesA fixed-dose approach to conducting emamectin benzoate tolerance assessments on field-collected sea lice, Lepeophtheirus salmonis.The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.HIV replication and latency in a humanized NSG mouse model during suppressive oral combinational ART.Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions.
P2860
Q28541096-D63B7702-9FEC-497A-A370-463DDF51F0BAQ33371080-8581F397-F145-4506-9742-8846CD402546Q33518011-FFB1E3B9-6156-41CB-8390-2D99700783BAQ34635175-1E003D7A-7A8D-4161-BD5C-A81535AD336DQ34664004-E36FA0B5-D0DC-43D2-93E7-4F1C63AC01A2Q34754376-B2CC7028-49EC-450E-B198-98EE16D12E05Q35093189-AE180011-94AE-492A-A70D-8B2BF125BA6BQ35867025-1BD08651-FB13-441F-9DDA-779C926A945AQ35938490-51BABB58-5272-4EDA-9750-88E74DBACC8EQ36018556-5E994B78-E21D-417B-9C12-894964B72918Q36105896-5E048D3B-50BA-4A38-BD4A-098BD3644412Q36190834-C3436CB6-DD47-4BA5-9426-CFE2F0EB8278Q36298353-04A68147-7AA7-4C78-9D29-02AFF79851ACQ37346125-7422A6B1-BFCE-4075-BBF3-B86357280A9DQ38853255-9EA40DF5-F99D-42C5-9011-8DD8F6E4E36FQ38872693-8AD3E1C6-70FF-4E47-B749-109E969434C8Q40048002-7DC35170-8F85-4E69-B905-083E0D55C5DAQ40219167-86516D0B-69A9-4E48-A8EA-6B401BEE3380Q40375804-218B4095-BDF3-4499-866B-AA79A113E2A8Q40398634-36414165-FFA4-4515-A858-A246F0F91B0DQ42587317-49EC66EF-0EF7-4981-8A4D-562265455845Q42698346-C526E482-FD9E-4B89-9D74-D1DF4680F43FQ43435596-9B3CB25F-F254-457D-BED6-95F69CE3DC78Q43846085-EA0B6095-5CB3-479B-9680-09AD522DAA99Q49990061-4D72D4A2-8614-47A6-A5AC-41C36EAFB9CBQ51202282-A4F9212C-C67B-49D5-9FFC-6B9DF1F50912
P2860
Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.
@ast
Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.
@en
type
label
Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.
@ast
Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.
@en
prefLabel
Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.
@ast
Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.
@en
P2860
P356
P1476
Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.
@en
P2093
Judith S Currier
Obiamiwe C Umeh
P2860
P304
P356
10.1517/17425255.2.2.273
P407
P577
2006-04-01T00:00:00Z